Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Molecular Pathways

Molecular Pathways: Interleukin-15 Signaling in Health and in Cancer

Anjali Mishra, Laura Sullivan and Michael A. Caligiuri
Anjali Mishra
The Divisions of Dermatology and Hematology, Department of Internal Medicine, The Comprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Sullivan
The Divisions of Dermatology and Hematology, Department of Internal Medicine, The Comprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael A. Caligiuri
The Divisions of Dermatology and Hematology, Department of Internal Medicine, The Comprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-12-3603 Published April 2014
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Interleukin-15 (IL-15) is a proinflammatory cytokine involved in the development, survival, proliferation, and activation of multiple lymphocyte lineages utilizing a variety of signaling pathways. IL-15 utilizes three distinct receptor chains in at least two different combinations to signal and exert its effects on the immune system. The binding of IL-15 to its receptor complex activates an “immune-enhancing” signaling cascade in natural killer cells and subsets of T cells, as well as the induction of a number of proto-oncogenes. Additional studies have explored the role of IL-15 in the development and progression of cancer, notably leukemia of large granular lymphocytes, cutaneous T-cell lymphoma, and multiple myeloma. This review provides an overview of the molecular events in the IL-15 signaling pathway and the aberrancies in its regulation that are associated with chronic inflammation and cancer. We briefly explore the potential therapeutic opportunities that have arisen as a result of these studies to further the treatment of cancer. These involve both targeting the disruption of IL-15 signaling as well as IL-15–mediated enhancement of innate and antigen-specific immunity. Clin Cancer Res; 20(8); 2044–50. ©2014 AACR.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

CME Staff Planners' Disclosures

The members of the planning committee have no real or apparent conflict of interest to disclose.

Learning Objectives

Upon completion of this activity, the participant should have a better understanding of IL-15 signaling in physiologic and pathologic conditions and the potential therapeutic development targeting this signaling pathway in inflammation and cancer.

Acknowledgment of Financial or Other Support

This activity does not receive commercial support.

Background

Cytokines play a critical role during the host's immune response against infectious pathogens and malignant transformation. One such cytokine, interleukin-15 (IL-15), is central to the development, survival, and activation of natural killer (NK), T, and B cells (1–5). Discovered in 1994, IL-15 is a member of the “four α-helix bundle” cytokine family that signals via the common γ chain and the IL-2 receptor (IL-2R)-β chain, and as a result the two cytokines share select biologic functions (6–8). Here, we discuss the structure, regulation, and biologic functions of IL-15 in a wide variety of cell lineages as well as its role in genesis of cancer.

The human and mouse IL-15 gene have approximately 73% sequence homology and are mapped on chromosome 4 and 8, respectively (9). The DNA sequence of the human IL-15 gene consists of six protein-coding exons and five introns compared with eight exons and seven introns in the mouse (9, 10). The presence of two different signal peptides in the IL-15 gene results in alternative splicing and the subsequent generation of two IL-15 isoforms in both human and mouse (11). Although both the long signal peptide (LSP) and short signal peptide (SSP) isoforms produce mature proteins, they each have distinct intracellular trafficking, localization, and secretion patterns (11, 12). The LSP isoform is primarily located in the Golgi apparatus, early endosomes, and endoplasmic reticulum and is often secreted from the cell as a soluble protein. The SSP isoform is confined to the cytoplasm and nucleus, suggesting its role as a transcriptional regulator (11–16).

IL-15 transcript is abundantly produced by a large variety of tissues and cell types: (i) tissues include the placenta, skeletal muscle, kidney, lung, and heart tissue; and (ii) cell types include epithelial cells, fibroblasts, keratinocytes, nerve cells, monocytes, macrophages, and dendritic cells (6, 17–20). Transcriptional activation of IL-15 occurs via the binding of NF-κB and IRF-E to the 5′ regulatory region of IL-15, among other active motifs such as GC-binding factor (GCF), myb, and INF2 (20–26). Despite the abundant expression of IL-15 transcript, IL-15 protein is stringently controlled and expressed primarily within monocytes, macrophages, and dendritic cells (6, 17, 18). This discrepancy between IL-15 transcript and protein expression is due to complex translation and intracellular protein trafficking culminating in barely detectable levels of the protein in vivo. IL-15 posttranscriptional checkpoints include a complex 5′-untranslated region (UTR) containing (i) multiple AUG sequences upstream of the initiation codon; (ii) a C-terminal negative regulatory element; and (iii) an inefficient signal peptide (12, 14, 17, 23, 27). Collectively, these mechanisms serve to limit IL-15 protein production and secretion from its vast stores of transcript.

Despite the lack of homology in the amino acid sequence between IL-15 and IL-2, the mature IL-15 protein binds to the IL-2Rβγ heterodimer, activating the intracellular signal leading to cell activation (6, 7, 28, 29). The third component of the IL-15R complex is a unique α-chain (IL-15Rα). In contrast with the IL-2Rα chain that binds IL-2 with low affinity and confers high affinity for IL-2 only when noncovalently linked the IL-2Rβγ complex, IL-15Rα is by itself a high-affinity receptor for IL-15 (30). Once IL-15 is secreted out of the cell, it binds to either the membrane bound or the soluble form of IL-15Rα and is presented in trans to and bound by the IL-2Rβγ complex expressed on nearby effector cells to initiate cellular activation (31).

IL-15 utilizes select Janus-associated kinases (JAK) and signal transducer and activator of transcription (STAT) proteins as a means of initiating signal transduction for cellular activation (32). In lymphocytes, binding of IL-15 to the IL-2/15Rβγ heterodimer induces JAK1 activation that subsequently phosphorylates STAT3 via the β-chain and JAK3/STAT5 activation via its γ-chain (refs. 33, 34; Fig. 1). Phosphorylated STAT3 and STAT5 proteins form heterodimers that then translocate to the nucleus, where they activate transcription of the antiapoptotic protein bcl-2 and proto-oncogenes c-myc, c-fos, and c-jun (26, 35–37). Mice that have genetic disruption of IL-15, JAK3, or STAT5 show a profound lymphoid cell deficiency (4, 38–40).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Intracellular signaling of IL-15. In one scenario (right), IL-15 binds to its high-affinity IL-15Rα expressed on an antigen-presenting cell and in turn is presented in trans to the IL-2/15Rβγ heterodimer. From there, effector cell activation can proceed via three distinct pathways: one involves JAK/STAT activation with the phosphorylated STAT proteins forming a heterodimer and trafficking to the nucleus for transcriptional activation; a second pathway involves the recruitment of Shc to a phosphorylated site on the IL-2/15Rβ chain followed by activation of Grb2. From there, Grb2 can proceed down the PI3K pathway to phosphorylate Akt, or can bind the guanine nucleotide exchange factor SOS to activate RAS–RAF and ultimately MAPK. Each contributes to effector cell survival and activation. In mast cells (left), IL-15 signals through a unique receptor chain, IL-15RX, to activate the JAK2/STAT5 pathway. IL-15 can also bind to the common γ-chain to transmit its signals via Tyk2/STAT6 for initiation of a survival (Bcl-XL) and a Th2 immune response. Therapeutic interventions using anti-IL-15R antibody prevent binding and signaling of IL-15 through its receptor. Pharmacologic inhibitors targeting the JAK/STAT pathway prevent activation and translocation of the STAT heterodimer to the nucleus. Finally, proteasomal inhibitors such as bortezomib prevent activation of NF-κB and Myc. Each of these therapies targets IL-15 signaling in malignant cells, but may have consequences for normal cells dependent upon IL-15.

Akt is activated via a phosphoinositide 3-kinase (PI3K)-dependent pathway, and in lymphocytes, this occurs despite the absence of PI3K-binding sites on the IL-2/15Rβγ (41, 42). The signaling mechanism utilizes an adaptor protein, Shc, which binds to a phosphotyrosine residue on the IL-2/15Rβ, resulting in activation of Grb2 and onto AKT via the ShcEmbedded ImageGrb2Embedded ImageGab2Embedded ImagePI3KEmbedded ImageAkt signaling pathway to increase cell proliferation and/or survival (ref. 41; Fig. 1). In a third signaling pathway that follows the trans-presentation of IL-15 to IL-2/15Rβγ and Shc-mediated activation of Grb2, the latter binds to the guanine nucleotide exchange factor SOS to form a Grb2–SOS complex that then activates the Ras–Raf pathway by facilitating the removal of GDP from a member of the Ras subfamily that in turn activates the mitogen-activated protein kinase (MAPK) pathway for cellular proliferation (Fig. 1; refs. 43, 44). Thus, IL-15–mediated Grb2 phosphorylation regulates both the PI3K and MAPK pathways. Collectively, these signaling mechanisms induce expression and activation of downstream effector molecules such as c-myc, c-fos, c-jun, Bcl-2, and NF-κB (36).

In contrast with lymphocytes, mast cells express a distinct receptor, termed IL-15RX, to activate the JAK2/STAT5 pathway (45). Murine mast cells treated with IL-15 seem to engage the IL-2/15Rγ chain to induce rapid phosphorylation of Tyk2/STAT6 for initiation of a Th2 type immune response (ref. 46; Fig. 1). In neutrophils, IL-15 has been shown to upregulate the antiapoptotic gene Mcl-1 through the MAPK pathway (47, 48).

Functionally, IL-15 supports cell expansion and maintenance by (i) inducing strong proliferative signals via JAK/STAT and Ras/MAPK signaling pathways and (ii) preventing cell death by increasing antiapoptotic proteins Bcl-2 and Bcl-Xl, as well as decreasing proapoptotic proteins Bim and Puma through activation of the PI3K pathway (24, 32, 33, 36, 43, 44). In addition, IL-15 enhances the cytotoxic effector functions of lymphocytes by increasing the production of a cytolytic pore forming protein, perforin, and death-inducing enzymes, granzymes A/B, through all three pathways (39, 40, 49). IL-15 signaling is also well known to evoke a Th1 immune response by inducing release of IFN-γ and TNF-α; however, it can also trigger a Th2 response through release of IL-4 and IL-5 in activated human T cells (50, 51). Similarly, in mast cells and monocytes, IL-15 induces the release of IL-4 and the chemokine IL-8, respectively (46, 52). In addition to increasing expression of chemokine receptors in lymphocytes, IL-15 is a potent chemoattractant, thus inducing infiltration of T and NK cells at the site of its production (53, 54).

Clinical–Translational Advances

Targeting IL-15 in cancer

The antitumor effect of IL-15 on the immune system has been well documented in experimental systems (55); nonetheless, accumulating evidence suggests that IL-15 can also initiate and promote certain types of malignancies.

Multiple myeloma is a disease characterized by the accumulation of malignant plasma cells in the bone marrow and is particularly sensitive to IL-15 signaling. Exploring expression patterns of the IL-15R subunits in six multiple myeloma cell lines, as well as in the neoplastic cell fraction of 14 patients with multiple myeloma, Tinhofer and colleagues found that malignant plasma cells expressed all three components of the IL-15R heterotrimer (56). Although healthy B cells from normal donors downregulate IL-15Rα in response to IL-15, multiple myeloma cells do not exhibit such a reduction in response to IL-15 stimulation. In vitro, IL-15 overexpression in malignant plasma cells protects them from spontaneous apoptosis as well as a broader range of activation-induced cell death (56). These data suggest that multiple myeloma cells can inhibit apoptosis and sustain themselves via autocrine IL-15 stimulation, thereby becoming less dependent upon their microenvironment. Further studies, however, are needed to elucidate the cellular mechanisms of IL-15–mediated signaling in multiple myeloma pathogenesis.

IL-15 is a growth and viability factor for malignant T cells in cutaneous T-cell lymphoma (CTCL), a lymphoproliferative disorder characterized by migration and expansion of malignant CD4+ T cells in the skin (57). Skin lesion and peripheral blood T cells of patients with CTCL show overexpression of IL-15 mRNA and protein (57, 58). Although not yet directly proven, IL-15 is thought to play an important role in the epidermotropism found in CTCL, given its aberrant expression in the skin of these patients and its strong chemoattractive properties for T cells (57, 59). IL-15 expression data from patients with CTCL strongly support the notion that in the early stages of CTCL, survival of malignant CD4+ T cells is dependent on IL-15 supplied from the microenvironment, but as the disease progresses, malignant cells may sustain their own growth through autocrine IL-15 production and signaling. More importantly, IL-15–mediated JAK1 and JAK3 phosphorylation results in constitutive STAT activation that contributes significantly to the growth and survival of malignant T cells in patients with CTCL (60, 61). Of note, exposure of CD4+ CTCL cells to IL-15 results in increased expression of antiapoptotic bcl-2 via the upregulation of STAT5 and c-myb, suggesting a protective mechanism of cell survival that is not present in nonmalignant CD4+ cells (62). Collectively, these results suggest that IL-15 likely plays a role in the pathogenesis of CTCL, acting as a potent chemoattractant of T cells to the skin, as a paracrine and autocrine survival and growth factor for malignant cells as well as an inhibitor of activation-induced cell death.

IL-15 was codiscovered in the Waldmann laboratory while studying the human T-cell lymphotrophic virus-1 (HTLV-1)-infected T-cell line, HUT102, in the absence of IL-2 (7). It was subsequently learned that the Tax protein of the virus induced the infected T cells to express both IL-15 and IL-15Rα (20). Thus, IL-15–mediated autocrine growth led to transformation of HTLV-1–associated adult T-cell leukemia/lymphoma (63).

Patients with leukemia of large granular lymphocytes (LGL) show increased serum levels of soluble IL-15Rα and constitutive expression of the IL-2/15Rβγ and membrane-bound form of IL-15 in leukemic blasts (64, 65). These data, and the fact that IL-15 is critical for the development and survival of both normal LGL (5, 66) and their malignant counterparts (67), support a role of IL-15 in LGL leukemia. Notably, two human LGL cell lines established from patients with CD3− LGL leukemia show requirement of IL-2 or IL-15 signaling via the IL-2/15Rβγ for survival and proliferation ex vivo (68, 69). While short-term exposure of IL-15 causes enhanced proliferation, cytokine production, and cytotoxic functions in normal LGLs (32–34, 39, 40), chronic IL-15–mediated activation via the JAK/STAT pathway, especially STAT3 and STAT5, can be leukemogenic. Somatic mutations in the SH2 domain of STAT3 have been discovered at the frequency of 40% in T-LGL leukemia and 30% in NK-LGL leukemia patients (70, 71). Unprecedented in the cancer genome, a novel somatic mutation in the STAT5b gene has been discovered in 2% of patients with aggressive LGL leukemia (72). Because IL-15 signaling and STAT3/STAT5b somatic mutations increase transcriptional activity of STAT proteins, the evidence suggests that the IL-15 signaling pathway is critical for the genesis of LGL leukemia. Indeed, transgenic mice engineered to overexpress IL-15 develop spontaneous T-LGL and NK-LGL leukemia that exhibits hallmarks of the human disease (73, 74). More importantly, chronic exposure to IL-15 alone is sufficient to initiate malignant transformation of wild-type mouse LGL through two distinct pathways, both of which are regulated by IL-15–mediated induction of Myc (75). In the first cascade, IL-15 mediates “Myc”-induced overexpression of aurora kinase A and B, resulting in centrosome amplification and consequent chromosomal instability. In the second pathway, Myc induces the downregulation of microRNA (miR)-29b, which in turn increases the expression of DNA methyltransferases and the methylation of genomic DNA, furthering chromosomal instability and silencing key tumor suppressor genes (75).

Proteasome inhibition by bortezomib impairs the miR-29b–mediated signaling cascade by inhibiting binding of the “Myc/NF–κB/Hdac1” corepressor complex at the miR-29b promoter (76). It is noteworthy that IL-15 reduces expression of the proapoptotic protein “Bid” in LGL leukemia via a proteasome-dependent mechanism, thereby protecting malignant cells from apoptosis, which can be reversed by blocking both IL-15 and IL-15Rα. In human LGL leukemic cells, induction of Bid by the proteasome inhibitor bortezomib increased leukemic cell death, suggesting that this could be an effective treatment option for this disease (77). Furthermore, in vivo administration of a novel formulation of bortezomib cured this otherwise fatal malignancy in mice with late stages of the disease (75), thus offering a new approach to treating patients with aggressive LGL leukemia.

Another therapeutic approach has been to use the monoclonal antibody Mikβ1 to block the presentation of IL-15 to the IL-2/IL-15Rβ thereby inhibiting proliferation of an IL-15–dependent cell line, Kit-225, in vitro. Though successful in vitro, clinical trials with Mikβ1 antibody (both mouse and humanized antibody) have thus far not produced notable clinical responses in patients with LGL leukemia (78, 79). In a recent phase I clinical trial, 9 CD3+CD8+CD122+ T-LGL leukemic patients were treated with a single intravenous dose of 0.5, 1.0, or 1.5 mg/kg of Mikβ1 (3 patients/group), and these patients showed neither antibody associated toxicity nor clinical response (78). A phase I–II clinical trial utilizing the same antibody in patients with fatal HTLV-1–associated T-cell leukemia is ongoing (80). Finally, as a variety of STAT3 inhibitors come forth to the clinic, it will be important to screen LGL leukemia patients for STAT3 mutations for inclusion in early-phase clinical studies (81).

IL-15 in clinical cancer therapy

Early trials in several solid tumors are showing remarkable clinical responses in patients who are treated with agents that block negative regulators of T-cell activation, i.e., CTLA-4 and PD-1 (82–84). Likewise, transplantation of haploidentical, KIR-ligand mismatched, T-cell–depleted stem cells to patients with acute myeloid leukemia has yielded promising results (85). In both instances, it is likely that the critical effector lymphocyte populations (i.e., cytotoxic T cells and NK cells, respectively) are activated by IL-15, which is now being investigated in several phase I clinical trials as a single agent (80, 86–90). Thus, once proper dosing and delivery schedule are achieved with IL-15, a combination with these immunologic checkpoint inhibitors will hopefully be investigated to further improve response rates without exacerbating autoreactivity against nonmalignant tissues. The soluble IL-15Rα/IL-15 dimer is also in clinical development and might offer enhanced pharmacodynamic and pharmacokinetic properties over IL-15 alone (91). In contrast with IL-2, IL-15 does not seem to expand regulatory T cells that exert an immunosuppressive effect (92–94). Experimental studies comparing the two cytokines in vivo would suggest a significant difference in the antitumor potency mediated by T cells that favors IL-15 (55).

Conclusions

IL-15 is an important cytokine in the regulation of the normal host immune response and thus likely has a role in protection against pathogens and malignant transformation. The molecule utilizes a variety of signaling pathways to control lymphocyte development, survival, proliferation, and activation. Chronic stimulation can lead to malignant transformation of T and NK cells in experimental systems, and clinical data from patients with CTCL, HTLV-1, and LGL leukemia seem to support its oncogenic properties. Harnessing IL-15′s powerful properties to enhance lymphocyte effector function in the setting of malignancy is likely to take shape over the next decade, leading to its broad use in the treatment of both hematologic and solid tumor malignancies.

Authors' Contributions

Writing, review, and/or revision of the manuscript: A. Mishra, M.A. Caligiuri

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): L. Sullivan

Grant Support

This work was supported by The American Society of Hematology (to A. Mishra) and NCI grants CA16058, CA95426, CA163205, CA68458, and CA89341 (to M.A. Caligiuri).

  • Received December 9, 2013.
  • Revision received January 31, 2014.
  • Accepted February 24, 2014.
  • ©2014 American Association for Cancer Research.

References

  1. 1.↵
    1. Carson WE,
    2. Giri JG,
    3. Lindemann MJ,
    4. Linett ML,
    5. Ahdieh M,
    6. Paxton R,
    7. et al.
    Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994;180:1395–403.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Armitage RJ,
    2. Macduff BM,
    3. Eisenman J,
    4. Paxton R,
    5. Grabstein KH
    . IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J Immunol 1995;154:483–90.
    OpenUrlAbstract
  3. 3.↵
    1. Mrozek E,
    2. Anderson P,
    3. Caligiuri MA
    . Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 1996;87:2632–40.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Kennedy MK,
    2. Glaccum M,
    3. Brown SN,
    4. Butz EA,
    5. Viney JL,
    6. Embers M,
    7. et al.
    Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000;191:771–80.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Cooper MA,
    2. Bush JE,
    3. Fehniger TA,
    4. VanDeusen JB,
    5. Waite RE,
    6. Liu Y,
    7. et al.
    In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 2002;100:3633–8.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Grabstein KH,
    2. Eisenman J,
    3. Shanebeck K,
    4. Rauch C,
    5. Srinivasan S,
    6. Fung V,
    7. et al.
    Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994;264:965–8.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Bamford RN,
    2. Grant AJ,
    3. Burton JD,
    4. Peters C,
    5. Kurys G,
    6. Goldman CK,
    7. et al.
    The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A 1994;91:4940–4.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Ring AM,
    2. Lin JX,
    3. Feng D,
    4. Mitra S,
    5. Rickert M,
    6. Bowman GR,
    7. et al.
    Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat Immunol 2012;13:1187–95.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Anderson DM,
    2. Johnson L,
    3. Glaccum MB,
    4. Copeland NG,
    5. Gilbert DJ,
    6. Jenkins NA,
    7. et al.
    Chromosomal assignment and genomic structure of Il15. Genomics 1995;25:701–6.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Krause H,
    2. Jandrig B,
    3. Wernicke C,
    4. Bulfone-Paus S,
    5. Pohl T,
    6. Diamantstein T
    . Genomic structure and chromosomal localization of the human interleukin 15 gene (IL-15). Cytokine 1996;8:667–74.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Tagaya Y,
    2. Kurys G,
    3. Thies TA,
    4. Losi JM,
    5. Azimi N,
    6. Hanover JA,
    7. et al.
    Generation of secretable and nonsecretable interleukin 15 isoforms through alternate usage of signal peptides. Proc Natl Acad Sci U S A 1997;94:14444–9.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Kurys G,
    2. Tagaya Y,
    3. Bamford R,
    4. Hanover JA,
    5. Waldmann TA
    . The long signal peptide isoform and its alternative processing direct the intracellular trafficking of interleukin-15. J Biol Chem 2000;275:30653–9.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Tagaya Y,
    2. Bamford RN,
    3. DeFilippis AP,
    4. Waldmann TA
    . IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity 1996;4:329–36.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Bamford RN,
    2. Battiata AP,
    3. Waldmann TA
    . IL-15: the role of translational regulation in their expression. J Leuko Biol 1996;59:476–80.
    OpenUrlAbstract
  15. 15.↵
    1. Meazza R,
    2. Verdiani S,
    3. Biassoni R,
    4. Coppolecchia M,
    5. Gaggero A,
    6. Orengo AM,
    7. et al.
    Identification of a novel interleukin-15 (IL-15) transcript isoform generated by alternative splicing in human small cell lung cancer cell lines. Oncogene 1996;12:2187–92.
    OpenUrlPubMed
  16. 16.↵
    1. Meazza R,
    2. Gaggero A,
    3. Neglia F,
    4. Basso S,
    5. Sforzini S,
    6. Pereno R,
    7. et al.
    Expression of two interleukin-15 mRNA isoforms in human tumors does not correlate with secretion: role of different signal peptides. Eur J Immunol 1997;27:1049–54.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Bamford RN,
    2. Battiata AP,
    3. Burton JD,
    4. Sharma H,
    5. Waldmann TA
    . Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotrophic virus type I region/IL-15 fusion message that lacks many upstream AUGs that normally attenuates IL-15 mRNA translation. Proc Natl Acad Sci U S A 1996;93:2897–902.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Blauvelt A,
    2. Asada H,
    3. Klaus-Kovtun V,
    4. Altman DJ,
    5. Lucey DR,
    6. Katz SI
    . Interleukin-15 mRNA is expressed by human keratinocytes Langerhans cells, and blood-derived dendritic cells and is downregulated by ultraviolet B radiation. J Invest Dermatol 1996;106:1047–52.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Lee YB,
    2. Satoh J,
    3. Walker DG,
    4. Kim SU
    . Interleukin-15 gene expression in human astrocytes and microglia in culture. Neuroreport 1996;7:1062–6.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Azimi N,
    2. Brown K,
    3. Bamford RN,
    4. Tagaya Y,
    5. Siebenlist U,
    6. Waldmann TA
    . Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-kappaB site. Proc Natl Acad Sci U S A 1998;95:2452–7.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Matsuyama T,
    2. Kimura T,
    3. Kitagawa M,
    4. Pfeffer K,
    5. Kawakami T,
    6. Watanabe N,
    7. et al.
    Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 1993;75:83–97.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Ogasawara K,
    2. Hida S,
    3. Azimi N,
    4. Tagaya Y,
    5. Sato T,
    6. Yokochi-Fukuda T,
    7. et al.
    Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 1998;391:700–3.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Azimi N,
    2. Shiramizu KM,
    3. Tagaya Y,
    4. Mariner J,
    5. Waldmann TA
    . Viral activation of interleukin-15 (IL-15): characterization of a virus-inducible element in the IL-15 promoter region. J Virol 2000;74:7338–48.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Huntington ND,
    2. Puthalakath H,
    3. Gunn P,
    4. Naik E,
    5. Michalak EM,
    6. Smyth MJ,
    7. et al.
    Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat Immunol 2007;8:856–63.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Washizu J,
    2. Nishimura H,
    3. Nakamura N,
    4. Nimura Y,
    5. Yoshikai Y
    . The NF-kappaB binding site is essential for transcriptional activation of the IL-15 gene. Immunogenetics 1998;48:1–7.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Waldmann TA,
    2. Tagaya Y
    . The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 1999;17:19–49.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Bamford RN,
    2. DeFilippis AP,
    3. Azimi N,
    4. Kurys G,
    5. Waldmann TA
    . The 5′ untranslated region, signal peptide, and the coding sequence of the carboxyl terminus of IL-15 participate in its multifaceted translational control. J Immunol 1998;160:4418–26.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Giri JG,
    2. Ahdieh M,
    3. Eisenman J,
    4. Shanebeck K,
    5. Grabstein K,
    6. Kumaki S,
    7. et al.
    Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 1994;13:2822–30.
    OpenUrlPubMed
  29. 29.↵
    1. Waldmann T,
    2. Tagaya Y,
    3. Bamford R
    . Interleukin-2, interleukin-15, and their receptors. Int Rev Immunol 1998;16:205–26.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Giri JG,
    2. Kumaki S,
    3. Ahdieh M,
    4. Friend DJ,
    5. Loomis A,
    6. Shanebeck K,
    7. et al.
    Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J 1995;14:3654–63.
    OpenUrlPubMed
  31. 31.↵
    1. Dubois S,
    2. Mariner J,
    3. Waldmann TA,
    4. Tagaya Y
    . IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 2002;17:537–47.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Johnston JA,
    2. Bacon CM,
    3. Finbloom DS,
    4. Rees RC,
    5. Kaplan D,
    6. Shibuya K,
    7. et al.
    Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc Natl Acad Sci U S A 1995;92:8705–9.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Miyazaki T,
    2. Kawahara A,
    3. Fujii H,
    4. Nakagawa Y,
    5. Minami Y,
    6. Liu ZJ,
    7. et al.
    Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science 1994;266:1045–7.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Lin JX,
    2. Migone TS,
    3. Tsang M,
    4. Friedmann M,
    5. Weatherbee JA,
    6. Zhou L,
    7. et al.
    The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 1995;2:331–9.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Shibuya H,
    2. Yoneyama M,
    3. Ninomiya-Tsuji J,
    4. Matsumoto K,
    5. Taniguchi T
    . IL-2 and EGF receptors stimulate the hematopoietic cell cycle via different signaling pathways: demonstration of a novel role for c-myc. Cell 1992;70:57–67.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Miyazaki T,
    2. Liu ZJ,
    3. Kawahara A,
    4. Minami Y,
    5. Yamada K,
    6. Tsujimoto Y,
    7. et al.
    Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation. Cell 1995;81:223–31.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Lord JD,
    2. McIntosh BC,
    3. Greenberg PD,
    4. Nelson BH
    . The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5. J Immunol 2000;164:2533–41.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Nosaka T,
    2. van Deursen JM,
    3. Tripp RA,
    4. Thierfelder WE,
    5. Witthuhn BA,
    6. McMickle AP,
    7. et al.
    Defective lymphoid development in mice lacking Jak3. Science 1995;270:800–2.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Imada K,
    2. Bloom ET,
    3. Nakajima H,
    4. Horvath-Arcidiacono JA,
    5. Udy GB,
    6. Davey HW,
    7. et al.
    Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J Exp Med 1998;188:2067–74.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Teglund S,
    2. McKay C,
    3. Schuetz E,
    4. van Deursen JM,
    5. Stravopodis D,
    6. Wang D,
    7. et al.
    Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 1998;93:841–50.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Gu H,
    2. Maeda H,
    3. Moon JJ,
    4. Lord JD,
    5. Yoakim M,
    6. Nelson BH,
    7. et al.
    New role for Shc in activation of the phosphatidylinositol 3-kinase/Akt pathway. Mol Cell Biol 2000;20:7109–20.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Ellery JM,
    2. Nicholls PJ
    . Alternate signalling pathways from the interleukin-2 receptor. Cytokine Growth Factor Rev 2002;13:27–40.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Adunyah SE,
    2. Wheeler BJ,
    3. Cooper RS
    . Evidence for the involvement of LCK and MAP kinase (ERK-1) in the signal transduction mechanism of interleukin-15. Biochem Biophys Res Commun 1997;232:754–8.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Steelman LS,
    2. Pohnert SC,
    3. Shelton JG,
    4. Franklin RA,
    5. Bertrand FE,
    6. McCubrey JA
    . JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004;18:189–218.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Tagaya Y,
    2. Burton JD,
    3. Miyamoto Y,
    4. Waldmann TA
    . Identification of a novel receptor/signal transduction pathway for IL-15/T in mast cells. EMBO J 1996;15:4928–39.
    OpenUrlPubMed
  46. 46.↵
    1. Masuda A,
    2. Matsuguchi T,
    3. Yamaki K,
    4. Hayakawa T,
    5. Kubo M,
    6. LaRochelle WJ,
    7. et al.
    Interleukin-15 induces rapid tyrosine phosphorylation of STAT6 and the expression of interleukin-4 in mouse mast cells. J Biol Chem 2000;275:29331–7.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Pelletier M,
    2. Ratthe C,
    3. Girard D
    . Mechanisms involved in interleukin-15-induced suppression of human neutrophil apoptosis: role of the anti-apoptotic Mcl-1 protein and several kinases including Janus kinase-2, p38 mitogen-activated protein kinase and extracellular signal-regulated kinases-1/2. FEBS Lett 2002;532:164–70.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Bouchard A,
    2. Ratthe C,
    3. Girard D
    . Interleukin-15 delays human neutrophil apoptosis by intracellular events and not via extracellular factors: role of Mcl-1 and decreased activity of caspase-3 and caspase-8. J Leukoc Biol 2004;75:893–900.
    OpenUrlAbstract/FREE Full Text
  49. 49.↵
    1. Farag SS,
    2. Caligiuri MA
    . Human natural killer cell development and biology. Blood Rev 2006;20:123–37.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Borger P,
    2. Kauffman HF,
    3. Postma DS,
    4. Esselink MT,
    5. Vellenga E
    . Interleukin-15 differentially enhances the expression of interferon-gamma and interleukin-4 in activated human (CD4+) T lymphocytes. Immunology 1999;96:207–14.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Mori A,
    2. Suko M,
    3. Kaminuma O,
    4. Inoue S,
    5. Ohmura T,
    6. Nishizaki Y,
    7. et al.
    IL-15 promotes cytokine production of human T helper cells. J Immunol 1996;156:2400–5.
    OpenUrlAbstract
  52. 52.↵
    1. Badolato R,
    2. Ponzi AN,
    3. Millesimo M,
    4. Notarangelo LD,
    5. Musso T
    . Interleukin-15 (IL-15) induces IL-8 and monocyte chemotactic protein 1 production in human monocytes. Blood 1997;90:2804–9.
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    1. Wilkinson PC,
    2. Liew FY
    . Chemoattraction of human blood T lymphocytes by interleukin-15. J Exp Med 1995;181:1255–9.
    OpenUrlAbstract/FREE Full Text
  54. 54.↵
    1. Allavena P,
    2. Giardina G,
    3. Bianchi G,
    4. Mantovani A
    . IL-15 is chemotactic for natural killer cells and stimulates their adhesion to vascular endothelium. J Leukoc Biol 1997;61:729–35.
    OpenUrlAbstract
  55. 55.↵
    1. Roychowdhury S,
    2. May KF Jr.,
    3. Tzou KS,
    4. Lin T,
    5. Bhatt D,
    6. Freud AG,
    7. et al.
    Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2. Cancer Res 2004;64:8062–7.
    OpenUrlAbstract/FREE Full Text
  56. 56.↵
    1. Tinhofer I,
    2. Marschitz I,
    3. Henn T,
    4. Egle A,
    5. Greil R
    . Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood 2000;95:610–8.
    OpenUrlAbstract/FREE Full Text
  57. 57.↵
    1. Dobbeling U,
    2. Dummer R,
    3. Laine E,
    4. Potoczna N,
    5. Qin JZ,
    6. Burg G
    . Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood 1998;92:252–8.
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    1. Leroy S,
    2. Dubois S,
    3. Tenaud I,
    4. Chebassier N,
    5. Godard A,
    6. Jacques Y,
    7. et al.
    Interleukin-15 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Dermatol 2001;144:1016–23.
    OpenUrlCrossRefPubMed
  59. 59.↵
    1. McInnes IB,
    2. al-Mughales J,
    3. Field M,
    4. Leung BP,
    5. Huang FP,
    6. Dixon R,
    7. et al.
    The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med 1996;2:175–82.
    OpenUrlCrossRefPubMed
  60. 60.↵
    1. Marzec M,
    2. Liu X,
    3. Kasprzycka M,
    4. Witkiewicz A,
    5. Raghunath PN,
    6. El-Salem M,
    7. et al.
    IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes. Blood 2008;111:2181–9.
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    1. Marzec M,
    2. Halasa K,
    3. Kasprzycka M,
    4. Wysocka M,
    5. Liu X,
    6. Tobias JW,
    7. et al.
    Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. Cancer Res 2008;68:1083–91.
    OpenUrlAbstract/FREE Full Text
  62. 62.↵
    1. Qin JZ,
    2. Zhang CL,
    3. Kamarashev J,
    4. Dummer R,
    5. Burg G,
    6. Dobbeling U
    . Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells. Blood 2001;98:2778–83.
    OpenUrlAbstract/FREE Full Text
  63. 63.↵
    1. Kukita T,
    2. Arima N,
    3. Matsushita K,
    4. Arimura K,
    5. Ohtsubo H,
    6. Sakaki Y,
    7. et al.
    Autocrine and/or paracrine growth of adult T-cell leukaemia tumour cells by interleukin 15. B J Haematol 2002;119:467–74.
    OpenUrlCrossRefPubMed
  64. 64.↵
    1. Zambello R,
    2. Facco M,
    3. Trentin L,
    4. Sancetta R,
    5. Tassinari C,
    6. Perin A,
    7. et al.
    Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. Blood 1997;89:201–11.
    OpenUrlAbstract/FREE Full Text
  65. 65.↵
    1. Chen J,
    2. Petrus M,
    3. Bamford R,
    4. Shih JH,
    5. Morris JC,
    6. Janik JE,
    7. et al.
    Increased serum soluble IL-15Ralpha levels in T-cell large granular lymphocyte leukemia. Blood 2012;119:137–43.
    OpenUrlAbstract/FREE Full Text
  66. 66.↵
    1. Carson WE,
    2. Ross ME,
    3. Baiocchi RA,
    4. Marien MJ,
    5. Boiani N,
    6. Grabstein K,
    7. et al.
    Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro. J Clin Invest 1995;96:2578–82.
    OpenUrlCrossRefPubMed
  67. 67.↵
    1. Yu J,
    2. Mitsui T,
    3. Wei M,
    4. Mao H,
    5. Butchar JP,
    6. Shah MV,
    7. et al.
    NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. J Clin Invest 2011;121:1456–70.
    OpenUrlCrossRefPubMed
  68. 68.↵
    1. Gong JH,
    2. Maki G,
    3. Klingemann HG
    . Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994;8:652–8.
    OpenUrlPubMed
  69. 69.↵
    1. Robertson MJ,
    2. Cochran KJ,
    3. Cameron C,
    4. Le JM,
    5. Tantravahi R,
    6. Ritz J
    . Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol 1996;24:406–15.
    OpenUrlPubMed
  70. 70.↵
    1. Koskela HL,
    2. Eldfors S,
    3. Ellonen P,
    4. van Adrichem AJ,
    5. Kuusanmaki H,
    6. Andersson EI,
    7. et al.
    Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012;366:1905–13.
    OpenUrlCrossRefPubMed
  71. 71.↵
    1. Jerez A,
    2. Clemente MJ,
    3. Makishima H,
    4. Koskela H,
    5. Leblanc F,
    6. Peng Ng K,
    7. et al.
    STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 2012;120:3048–57.
    OpenUrlAbstract/FREE Full Text
  72. 72.↵
    1. Rajala HL,
    2. Eldfors S,
    3. Kuusanmaki H,
    4. van Adrichem AJ,
    5. Olson T,
    6. Lagstrom S,
    7. et al.
    Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 2013;121:4541–50.
    OpenUrlAbstract/FREE Full Text
  73. 73.↵
    1. Fehniger TA,
    2. Suzuki K,
    3. Ponnappan A,
    4. VanDeusen JB,
    5. Cooper MA,
    6. Florea SM,
    7. et al.
    Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med 2001;193:219–31.
    OpenUrlAbstract/FREE Full Text
  74. 74.↵
    1. Yokohama A,
    2. Mishra A,
    3. Mitsui T,
    4. Becknell B,
    5. Johns J,
    6. Curphey D,
    7. et al.
    A novel mouse model for the aggressive variant of NK cell and T cell large granular lymphocyte leukemia. Leuk Res 2010;34:203–9.
    OpenUrlCrossRefPubMed
  75. 75.↵
    1. Mishra A,
    2. Liu S,
    3. Sams GH,
    4. Curphey DP,
    5. Santhanam R,
    6. Rush LJ,
    7. et al.
    Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell 2012;22:645–55.
    OpenUrlCrossRefPubMed
  76. 76.↵
    1. Liu S,
    2. Wu LC,
    3. Pang J,
    4. Santhanam R,
    5. Schwind S,
    6. Wu YZ,
    7. et al.
    Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 2010;17:333–47.
    OpenUrlCrossRefPubMed
  77. 77.↵
    1. Hodge DL,
    2. Yang J,
    3. Buschman MD,
    4. Schaughency PM,
    5. Dang H,
    6. Bere W,
    7. et al.
    Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias. Cancer Res 2009;69:3986–94.
    OpenUrlAbstract/FREE Full Text
  78. 78.↵
    1. Waldmann TA,
    2. Conlon KC,
    3. Stewart DM,
    4. Worthy TA,
    5. Janik JE,
    6. Fleisher TA,
    7. et al.
    Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood 2013;121:476–84.
    OpenUrlAbstract/FREE Full Text
  79. 79.↵
    1. Morris JC,
    2. Janik JE,
    3. White JD,
    4. Fleisher TA,
    5. Brown M,
    6. Tsudo M,
    7. et al.
    Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia. Proc Natl Acad Sci U S A 2006;103:401–6.
    OpenUrlAbstract/FREE Full Text
  80. 80.↵
    National Institute of Neurological Disorders and Stroke (NINDS). Hu Mik-Beta-1 to treat HTLV-1-associated myelopathy/tropical spastic paraparesis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 Nov 15]. Available from: http://clinicaltrials.gov/ct2/show/NCT00076843.
  81. 81.↵
    1. Epling-Burnette PK,
    2. Liu JH,
    3. Catlett-Falcone R,
    4. Turkson J,
    5. Oshiro M,
    6. Kothapalli R,
    7. et al.
    Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001;107:351–62.
    OpenUrlCrossRefPubMed
  82. 82.↵
    1. Brahmer JR,
    2. Tykodi SS,
    3. Chow LQ,
    4. Hwu WJ,
    5. Topalian SL,
    6. Hwu P,
    7. et al.
    Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455–65.
    OpenUrlCrossRefPubMed
  83. 83.↵
    1. Topalian SL,
    2. Hodi FS,
    3. Brahmer JR,
    4. Gettinger SN,
    5. Smith DC,
    6. McDermott DF,
    7. et al.
    Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–54.
    OpenUrlCrossRefPubMed
  84. 84.↵
    1. Wolchok JD,
    2. Kluger H,
    3. Callahan MK,
    4. Postow MA,
    5. Rizvi NA,
    6. Lesokhin AM,
    7. et al.
    Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122–33.
    OpenUrlCrossRefPubMed
  85. 85.↵
    1. Ruggeri L,
    2. Capanni M,
    3. Urbani E,
    4. Perruccio K,
    5. Shlomchik WD,
    6. Tosti A,
    7. et al.
    Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097–100.
    OpenUrlAbstract/FREE Full Text
  86. 86.↵
    Masonic Cancer Center, University of Minnesota. Haploidentical donor natural killer cell infusion with IL-15 in acute myelogenous leukemia (AML). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 Nov 15]. Available from: http://clinicaltrials.gov/ct2/show/NCT01385423.
  87. 87.↵
    National Cancer Institute (NCI). Continuous infusion of rhIL-15 for adults with advanced cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 Nov 15]. Available from: http://clinicaltrials.gov/ct2/show/NCT01572493.
  88. 88.↵
    National Cancer Institute (NCI). Use of IL-15 after chemotherapy and lymphocyte transfer in metastatic melanoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 Nov 15]. Available from: http://clinicaltrials.gov/ct2/show/NCT01369888.
  89. 89.↵
    National Cancer Institute (NCI). NK white blood cells and interleukin in children and young adults with advanced solid tumors. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 Nov 15]. Available from: http://clinicaltrials.gov/ct2/show/NCT01875601.
  90. 90.↵
    National Cancer Institute (NCI). A phase I study of intravenous recombinant human IL-15 in adults with refractory metastatic malignant melanoma and metastatic renal cell cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 Nov 15]. Available from: http://clinicaltrials.gov/ct2/show/NCT01021059.
  91. 91.↵
    1. Chertova E,
    2. Bergamaschi C,
    3. Chertov O,
    4. Sowder R,
    5. Bear J,
    6. Roser JD,
    7. et al.
    Characterization and favorable in vivo properties of heterodimeric soluble IL-15.IL-15Ralpha cytokine compared to IL-15 monomer. J Biol Chem 2013;288:18093–103.
    OpenUrlAbstract/FREE Full Text
  92. 92.↵
    1. Cornish GH,
    2. Sinclair LV,
    3. Cantrell DA
    . Differential regulation of T-cell growth by IL-2 and IL-15. Blood 2006;108:600–8.
    OpenUrlAbstract/FREE Full Text
  93. 93.↵
    1. Shah MH,
    2. Freud AG,
    3. Benson DM Jr.,
    4. Ferkitich AK,
    5. Dezube BJ,
    6. Bernstein ZP,
    7. et al.
    A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer. Clin Cancer Res 2006;12:3993–6.
    OpenUrlAbstract/FREE Full Text
  94. 94.↵
    1. Zorn E,
    2. Nelson EA,
    3. Mohseni M,
    4. Porcheray F,
    5. Kim H,
    6. Litsa D,
    7. et al.
    IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006;108:1571–9.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Clinical Cancer Research: 20 (8)
April 2014
Volume 20, Issue 8
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Molecular Pathways: Interleukin-15 Signaling in Health and in Cancer
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Molecular Pathways: Interleukin-15 Signaling in Health and in Cancer
Anjali Mishra, Laura Sullivan and Michael A. Caligiuri
Clin Cancer Res April 15 2014 (20) (8) 2044-2050; DOI: 10.1158/1078-0432.CCR-12-3603

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Molecular Pathways: Interleukin-15 Signaling in Health and in Cancer
Anjali Mishra, Laura Sullivan and Michael A. Caligiuri
Clin Cancer Res April 15 2014 (20) (8) 2044-2050; DOI: 10.1158/1078-0432.CCR-12-3603
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Disclosure of Potential Conflicts of Interest
    • CME Staff Planners' Disclosures
    • Learning Objectives
    • Acknowledgment of Financial or Other Support
    • Background
    • Clinical–Translational Advances
    • Conclusions
    • Authors' Contributions
    • Grant Support
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Therapeutic Targeting of the Liver Microenvironment
  • Targeting the Protein Kinase Wee1 in Cancer
  • Metabolic Control of Histone Methylation and Gene Expression
Show more Molecular Pathways
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement